Marcie Glicksman, Ph.D., Co-Director, Laboratory for Drug Discovery at Harvard Neurodiscovery Center to give presentation on “Protein Kinase Inhibitors for Neurodegenerative Diseases” at GTCbio’s 6th Protein Kinases in Drug Discovery Conference on May 26-27, 2011 in Boston, MA
Dr. Glicksman will describe some of the challenges and promise of kinase inhibitors for neurodegenerative diseases. The LDDN has an established track record of progressing projects along the drug discovery pathway, from assay development and high-throughput screening through medicinal chemistry on lead compounds and testing candidate drugs in animal models of disease. Kinase targets are attractive drug discovery targets and there have been a number of successes in oncology, but what are the challenges of kinase targets for neurodegenerative diseases?
Dr. Glicksman has extensive experience in assay development, high throughput screening, as well as animal pharmacology and preclinical development. Before joining LDDN, she held positions at Descartes Therapeutics, Cubist, DuPont-Merck, and Cephalon. She has served on the Board of Directors and as Chairman of the Society for Biomolecular Sciences.
Also presenting at the Protein Kinase Conference are prestigious organizations including Abbott, Ansaris, Arqule, Avila Tx, Biogen Idec, Boehringer Ingelheim, Dana Farber, DE Shaw Research, Genentech, Harvard Medical School, Invitrogen, Millennium, Merck, Novartis, OSI Pharma, Pfizer, and other leaders in the kinase industry. For more information, please visit http://www.gtcbio.com.
